Dexrazoxane for anthracycline extravasation and GM-CSF for skin ulceration and wound healing

Lancet Oncol. 2004 May;5(5):320-1. doi: 10.1016/S1470-2045(04)01470-6.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / surgery
  • Chelating Agents / administration & dosage
  • Chelating Agents / therapeutic use*
  • Clinical Trials, Phase III as Topic
  • Combined Modality Therapy
  • Doxorubicin / adverse effects*
  • Extravasation of Diagnostic and Therapeutic Materials / drug therapy*
  • Extravasation of Diagnostic and Therapeutic Materials / etiology
  • Extravasation of Diagnostic and Therapeutic Materials / pathology
  • Female
  • Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage
  • Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use*
  • Humans
  • Infusions, Intravenous
  • Injections, Intralesional
  • Randomized Controlled Trials as Topic
  • Razoxane / administration & dosage
  • Razoxane / therapeutic use*
  • Skin Ulcer / chemically induced
  • Skin Ulcer / drug therapy
  • Skin Ulcer / pathology
  • Thorax
  • Wound Healing

Substances

  • Chelating Agents
  • Razoxane
  • Doxorubicin
  • Granulocyte-Macrophage Colony-Stimulating Factor